Podcasts about Boston Scientific

In this episode of Medsider Radio, we had a really engaging conversation with James (Jim) Corbett, CEO of AVITA Medical.AVITA Medical's RECELL system uses Spray-On Skin Cell technology to accelerate healing for patients with severe burns and wounds.  Jim brings nearly 40 years of medical device leadership experience to AVITA Medical. His career spans global commercial and operational roles, including President of Boston Scientific and General Manager of Scimed Life Systems. Jim has served as CEO of six companies, including three publicly traded entities — Microtherapeutics, ev3, and Alphatec Spine — as well as CathWorks, Home Diagnostics, and Vertos Medical.In this interview, Jim shares lessons from a career spanning global medtech leadership positions — including the importance of hands-on fundraising, adapting sales strategies as products mature, and how generating clinical evidence beyond FDA requirements serves commercial adoption.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Jim Corbett.

In this episode of Medsider Radio, we sat down with Todd Usen, CEO of Adagio Medical.Adagio specializes in catheter-based ablation technologies for the treatment of cardiac arrhythmias, with a focus on ventricular tachycardia (VT).  Todd has over three decades of leadership experience in the medical technology industry, with particular expertise in commercial strategy, operational performance, and business transformation. Before joining Adagio, Todd served as CEO of Minerva Surgical, a women's health company, and as CEO of Activ Surgical, a digital surgery startup. Todd has also served in executive positions at Olympus, United States Orthopedics, Smith and Nephew, and Boston Scientific.In this interview, Todd shares insights on making usability central to commercialization strategy, leveraging breakthrough designation beyond regulatory validation, and assembling effective boards by carefully selecting both investor and independent members who bring operational expertise.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Todd Usen.

Join HRS Board Member Prashanthan Sanders, MBBS, PhD, FHRS (University of Adelaide) as he discusses this exciting paper, presented at Heart Rhythm 2025. He is joined in the Heart Rhythm Tv Studio in San Diego, California by Louise Segan, MBBS, MPH (Alfred Health), and Takanori Yamaguchi, MD, PhD (Saga University). This discussion took place on-site at Heart Rhythm 2025.   https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)01245-7/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): T. Yamaguchi: Honoraria/Speaking/Consulting: Abbott Japan, Biotronik, Boston Scientific, Abbott Medical, Japan Medtronic, Inc., Daiichi Sankyo, Novartis, Japan Lifeline, Nihon Kohden, Bayer Healthcare Pharmaceuticals Japan, Boehringer Ingelheim L. Segan: Nothing to disclose.

I detta avsnitt av Parkinsonpodden är jag på träningsvecka på Rhodos med ett gäng från Parkinson Skåne. Resan arrangeras av Go fitness. Träning, sol, bad, god mat och trevligt umgänge under en vecka i maj. Du hör Jan Gleisner, arrangör och yogainstruktör, Josefin Smulan Liljegren, arrangör och tränare, Cecilia Mauritzon, deltagare och Bengt Pålsson, anhörig.Parkinsonpoddens annonsörer är Navamedic, AbbVie, Boston Scientific, Merz Therapeutics Nordics AB och CureMed Nordic AB. Företagen har ingen påverkan på programval eller innehåll.Programledare: Anders StålhammarTekniker/bollplank: Inge Amundsenhttp://www.parkinsonpodden.seanders@parkinsonpodden.sewww.alltomparkinson.se Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Latin Wealth Podcast, we dive into major developments shaping Latin America's economic and political landscape in 2025. From Costa Rica's quiet rise as a high-tech powerhouse to China's growing influence across Latin America — and the unexpected shift of Latin American migration from the U.S. to Spain — we break down what these global shifts mean for Latinos around the world.Segment 1: Costa Rica's Tech TransformationCosta Rica is becoming Latin America's high-tech hub, recording over $32 billion in exports in 2024. With investments from global tech giants like Intel and Boston Scientific, and a booming medical device sector, this Central American nation is showing the power of innovation, sustainability, and national branding. We discuss how this model could inspire other countries in the region.Segment 2: China's Visa-Free PlayChina is expanding visa-free travel to citizens of Brazil, Argentina, Chile, Peru, and Uruguay. This is more than a tourism policy — it's a strategic move to deepen China's presence in Latin America. We discuss what this means for global partnerships, trade routes, and diplomatic influence in the Western Hemisphere.Segment 3: “The American Dream is Over?”Trump's aggressive deportation policies are causing many Latin Americans to abandon the U.S. for Spain. We explore how political pressure, cultural ties, and economic opportunity are reshaping migration patterns, and what this means for Latinos chasing opportunity abroad.This episode covers:- Latin America's tech innovation and economic growth- China's bold diplomatic strategies in the region- How shifting immigration policies are changing the Latino diaspora- The future of the American Dream for Latin communities

Prashanthan Sanders, MBBS, PhD, FHRS, University of Adelaide is joined by Jenish Shroff, MBBS, MD, Australian National University, and Pugazhendhi Vijayaraman, MD, FHRS, Geisinger Heart Institute, to discuss this first-in-human feasibility study evaluated a novel helix-based leadless pacemaker (LPCSP) designed to achieve left bundle branch area pacing (LBBAP), a capability current LPs lack. The device was temporarily implanted via the internal jugular vein into the interventricular septum in 14 patients, with successful implantation in 10. Electrical performance metrics, including pacing threshold, R-wave amplitude, and impedance, were within acceptable clinical ranges. LBBAP capture was achieved in 5 patients, with no serious device-related adverse events in 85.7% of cases. The study supports the acute safety and feasibility of LPCSP for conduction system pacing.    https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02378-1/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): P. Vijayaraman: Honoraria/Speaking/Consulting: Biotronik, Boston Scientific, Abbott Medical, Medtronic, Inc. Research (Contracted Grants for PIs and Named Investigators only): Medtronic Fellowship Support: Medtronic J. Shroff: Nothing to disclose.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Johns Creek: Number One Best U.S. City to Live In, with Mayor John Bradberry and Brian Lynam, Boston Scientific (GNFCC 400 Insider, Episode 107) Join GNFCC CEO Kali Boatright in this episode of the GNFCC 400 Insider podcast as she chats with Johns Creek Mayor John Bradberry and Boston Scientific Senior Director Brian Lynam, discussing […] The post Johns Creek: Number One Best U.S. City to Live In, with Mayor John Bradberry and Brian Lynam, Boston Scientific appeared first on Business RadioX ®.

https://www.instagram.com/clau_qsi/  https://www.tiktok.com/@clau_qsi/  ¡Hola, hola!  En este episodio hablamos con Laura, Ingeniera Biomédica y actual alumna del MBA en Tecnologías Médicas y Sanitarias de Talento - EPHOS. ¡Una pasada!

Michael S. Lloyd, MD, FHRS, Emory University is joined by Edward P. Gerstenfeld, MD, MS, FHRS, University of California, San Francisco, and Christopher C Cheung, MD, MPH, FHRS, Sunnybrook HSC, University of Toronto, to discuss the VOLT-AF IDE study evaluated the safety and effectiveness of a novel balloon-based pulsed field ablation (PFA) catheter system for treating paroxysmal and persistent atrial fibrillation (PAF and PsAF). Conducted at 34 global sites, the study enrolled 394 subjects, with 320 included in the primary analysis. Acute pulmonary vein isolation (PVI) success was achieved in over 99% of veins, and primary serious adverse events occurred in only 1.9% of patients, with no significant complications like esophageal injury or hemolysis. Procedure metrics showed efficient operation times, and early 6-month data suggest promising effectiveness. These initial findings support the Volt™ PFA system as a safe and effective treatment option for AF.    https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02168-X/fulltext Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Arga Medtech, Circa Scientific Membership on Advisory Committees: Boston Scientific Contributor Disclosure(s):   E. Gerstenfeld: Honoraria/Speaking/Consulting: Medtronic, Boston Scientific, Biosense Webster, Abbott, Varian Medical Systems, Biotronik Other Non-Financial Relationships: Farapulse, Adagio Medical, Boston Scientific, Abbott Medical, Research (Contracted Grants for PIs and Named Investigators only): Abbott Medical Officer, Trustee, Director, Committee Chair, or Any Other Fiduciary Role: American College of Cardiology Foundation C. Cheung: Nothing to disclose.

Två Österrikiska ingenjörer har tillverkat en sko (NUSHU) som ska kunna göra det lättare för bl.a Parkinsonsjuka att gå. Hör Hans Crispin som haft Parkinsons sjukdom sedan 2008, och som köpte det första paret som kom till Sverige. Hans hade tidigare svårt att gå, men springer nu i trapporna och kan om han vill jogga på trottoaren.För ytterligare information maila:hans.crispin@hotmail.comParkinsonpoddens annonsörer är Navamedic, AbbVie, Boston Scientific, Merz Therapeutics Nordics AB och CureMed Nordic AB. Företagen har ingen påverkan på programval eller innehåll.Programledare: Anders StålhammarTekniker/bollplank: Inge Amundsenhttp://www.parkinsonpodden.seanders@parkinsonpodden.sewww.alltomparkinson.se Hosted on Acast. See acast.com/privacy for more information.

Sandeep A Saha, MD, MS, FHRS, Oregon Heart Center PC is joined by Saket Sanghai, MD, FHRS, Oregon Health & Science University, and Naga Venkata Krishna Chand Pothineni, MD, Kansas City Heart Rhythm Institute, to discuss how the study evaluated the effectiveness of implantable loop recorders (ILRs) in detecting arrhythmias in patients with hypertrophic cardiomyopathy (HCM). Traditional monitoring methods, like Holter monitors, often miss intermittent arrhythmic events in HCM patients. ILRs, offering continuous long-term monitoring, were found to identify clinically significant arrhythmias that might otherwise go undetected. The findings suggest that ILRs can play a crucial role in risk stratification and management of HCM patients, potentially guiding decisions regarding interventions such as implantable cardioverter-defibrillator (ICD) implantation. Overall, ILRs enhance the detection of arrhythmias in HCM, leading to improved patient care.    https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacep.2025.03.005 Host Disclosure(s): S. Saha: Honoraria/Speaking/Consulting Fee: Medtronic Membership on Advisory Committees: Medtronic Inc. Contributor Disclosure(s): S. Sanghai: Research: Siemens Healthcare Stocks (Publicly Traded): Apple Inc., Alphabet Inc., Amazon Stock Options (Publicly Traded): Intel K. Pothineni: Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Boston Scientific

In this episode of the Next Level Healing Podcast, Dr. Tara Perry interviews John K. Bates, Founder of Executive Speaking Success. John has trained and coached leaders at NASA—including the astronauts—GE Aerospace, US Navy Special Operations, Johnson & Johnson's JLABS, Boston Scientific, Google, Intuit, and many more. His programs consistently earn Net Promoter Scores of 92+, and his clients don't just thank him—they recommend him as the best leadership communication coach working today.Work with Dr. Tara PerryTune in every week for a new episode of Next Level Healing. Subscribe on your favorite podcasting platform and never miss an episode!

Mais de 10 milhões de pessoas no mundo são afetadas pelo mal de Parkinson, e esse número pode dobrar até 2050. Não há, ainda, cura, mas as terapias de estimulação cerebral profunda, conhecidas como DBS, combinam dispositivos digitais com implantes cerebrais para mudar a vida de quem sofre com doenças neurodegenerativas. Como funcionam esses marca-passos cerebrais e como a IA os torna ainda mais precisos? Conversamos com o diretor de neuromodulação da Boston Scientific no Brasil, Lucas Silva, para entender essa história, cheia de finais felizes.Links do episódioA página do LinkedIn de Lucas SilvaO site Viver com ParkinsonO documentário "Still - ainda sou Michael J. Fox", na Apple TV+A série "Shrink - Falando a Real", na Apple TV+O livro "The Ageless Brain: How to Sharpen and Protect Your Mind for a Lifetime", de Dale BredesenO livro "Uma viagem pelo cérebro. A via rápida para entender neurociência", de Carla Tieppo A The Shift é uma plataforma de conteúdo que descomplica os contextos da inovação disruptiva e da economia digital.Visite o site www.theshift.info e assine a newsletter

They're good dogs, especially when Kasey Labelle joins us to share her lifelong connection with puppies. She recounts her childhood with two family dogs before introducing Rhino, her beloved blue nose pitbull who chose her when he was just three weeks old and remained her companion for nearly 15 years. Kasey discusses how she's coped with Rhino's passing by becoming a dog walker, speaks passionately about the misconceptions surrounding pitbulls, and shares how Rhino's loving personality challenged those stereotypes. She also offers thoughtful advice for potential dog owners, emphasizing the importance of viewing dogs as family members and the different factors to consider when choosing the right dog.Guest BioKasey Labelle, CPWA (she/her) is a UX and design engineering leader with a passion for design systems and accessibility. In her current role as a Design Architect at iSeatz, she's leading the evolution of a design system that powers a white-label travel loyalty platform. Previously, she built and led the multi-disciplinary design system team and accessibility program at Boston Scientific, establishing 0-1 and 1-n strategies and serving as a player-coach. In her downtime, you can find her at the beach, an art museum, concert, or game night; walking dogs; obsessing over spreadsheets; traveling; or attending fine arts and crafts workshops with friends.LinksKasey's website: kaseyllabelle.comKasey on LinkedIn: linkedin.com/in/kaseyllabelleCreditsCover design by Raquel Breternitz.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Join host Prashanthan Sanders, MBBS, PhD, FHRS, and episode guests Jason G. Andrade, MD, FHRS, and Melanie Gunawardene, MD, as they discuss Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. This discussion was recorded in person at EHRA 2025 in Vienna, Austria. The article under discussion was presented at EHRA 2025 and simultaneously published in the New England Journal of Medicine.   https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2502280   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical   Contributor Disclosure(s): M. Gunawrdene: Honoraria/Speaking/Consulting: Farapulse, Abbott Medical, Boston Scientific, Medtronic, Biotronik, Luma Vision, Bristol Myers Squibb J. Andrade: Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Inc., Biosense Webster, Inc.

Alissa Coram and Justin Nielsen analyze Monday's market action and discuss key stocks to watch on Stock Market Today.

In this episode, a multidisciplinary panel of PE key opinion leaders share insights and challenge perceived myths within the landscape of PE real world evidence and care. Listen in for the latest data, contemporary treatment strategies, and preview anticipated future developments in this rapidly evolving field of PE.

In this episode, the Surgical Endoscopy team, accompanied by Chief Medical Officer Dr. Brian Dunkin of Boston Scientific, review primary and revisional endoscopic treatment options for bariatric patients. They focus on the emerging data available for procedures such as endoscopic sleeve gastroplasty (ESG) and endoscopic gastrojejunal revision (EGJR) and offer technical tips on how to perform the procedures. In addition, they discuss accessibility challenges for patients and provide insight into the future direction of bariatric endoscopy as a field.  Hosts: ·      Dr. Sullivan “Sully” Ayuso, Minimally Invasive Surgery, Endeavor Health (Evanston, IL), @SAyusoMD (Twitter) ·      Dr. Trevor Crafts, Minimally Invasive Surgeon, Rocky Mountain VA Medical Center (Denver, CO), @CraftsTrevor (Twitter)  ·      Dr. H. Masson Hedberg, Minimally Invasive Surgeon, Endeavor Health (Evanston, IL) ·      Dr. Michael Ujiki, Professor and Louis Biegler Chair of Surgery, Endeavor Health (Evanston, IL), @UjikiMike ·      Dr. Brian Dunkin, Chief Medical Officer at Boston Scientific, @briandunkinmd Learning Objectives:  -       Identify and Describe Common Endobariatric Procedures: Learners will be able to name and briefly describe at least three common endobariatric procedures discussed in the episode, including Endoscopic Sleeve Gastroplasty (ESG), Endoscopic GJ Revisions (Transoral Outlet Reduction - TORR/EGJR), and Intragastric Balloons, along with their historical context and evolution. -       Explain the Mechanism and Benefits of Endoscopic Sleeve Gastroplasty (ESG): Learners will be able to articulate the procedural technique of ESG, including the U-shaped suture pattern, its impact on gastric volume reduction, and the proposed mechanisms of weight loss, such as slowed gastric emptying and hormonal changes, as compared to laparoscopic sleeve gastrectomy. -       Discuss the Role of Technology and Training in Endobariatrics: Learners will be able to explain the significance of endoscopic suturing devices like the Overstitch in the advancement of endobariatric procedures and recognize the importance of specialized training, including the recommendations against fundal suturing for safety during the initial learning curve. -       Compare and Contrast Endobariatric Procedures with Surgical and Pharmacological Obesity Treatments: Learners will be able to discuss the position of endobariatric procedures as a "gap therapy" in the spectrum of obesity treatments, highlighting their benefits such as reduced invasiveness, lower complication rates, faster recovery, and increased patient access compared to surgery, as well as their potential role in conjunction with pharmacologic therapies like GLP-1 agonists. -       Recognize Key Considerations and Potential Complications of Endobariatric Procedures: Learners will be able to identify important technical considerations during ESG, such as achieving full-thickness bites while avoiding injury to adjacent organs, and describe common post-procedure issues associated with intragastric balloons, including nausea, vomiting, and the need for general anesthesia during removal. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity: https://pubmed.ncbi.nlm.nih.gov/39888616/ Surgical Endoscopy Series Ep. 1: An Introduction to Surgical Endoscopy: https://app.behindtheknife.org/podcast/surgical-endoscopy-series-ep-1-an-introduction-to-surgical-endoscopy Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Alissa Coram and Ken Shreve analyze Wednesday's market action and discuss key stocks to watch on Stock Market Today.

In this episode of Medsider Radio, we sat down with Randy Pritchard and Erica Rogers, leaders of Axena Health. Axena is transforming pelvic floor therapy with Leva, a device bringing clinically-proven, supervised pelvic floor muscle training into women's homes. Randy, CEO of Axena, brings nearly 25 years of healthcare experience to the company, most recently as CEO of Pillar Biosciences and previously holding leadership positions at Roche Diagnostics, where he spent 18 years developing commercial expertise. Erica, who sits on Axena's Board of Directors, spent a decade as President and CEO of Silk Road Medical, leading the company from early clinical trials through IPO and eventual acquisition by Boston Scientific. A returning guest to the podcast after nearly half a decade, Erica previously held roles at Medicine360, co-founded two other medical device companies, and spent over 12 years at Boston Scientific prior to her role at Silk Road.In this interview, they share essential medtech commercialization insights: identify your specific patient segment, build continuous clinical evidence, and communicate consistently with investors. Their experience offers invaluable lessons for medical device entrepreneurs navigating today's complex healthcare landscape.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Randy Pritchard and Erica Rogers.

Jacob Raymer is an internationally recognized speaker who addresses corporate, public and universityaudiences on the subjects of leadership roles and responsibilities, cultural transformation, and how to achieveorganizational excellence with the right behavior and sustainable long-term results. As the Shingo Institute'sformer Director of Education, Jacob co-created the Shingo Model and developed the foundational learningcourses taught at the Shingo Institute. He has trained Shingo examiners and thousands of individualsworldwide on how to assess and establish lean mindsets and method. In 2006, Jacob pioneered the concept ‘key behavior indicators' (KBIs). Today many world-wide organizations have now adopted this term and concept to expand their desired outcomes with key performance indicators(KPIs). By combining KPI and KBI, Jacob's consulting firm has led the development and application of behavior-based strategy deployment; building systems to drive the right behavior; and developing internal behavioralassessments. The United State Airforce invited Jacob to join a team of global subject matter experts to create their leanleadership development program (AFSO21) in 2006. He was commissioned to lead the leadershipdevelopment for United States Airforce Europe – working with leaders throughout 93 countries. His workchallenged leaders' mindsets around lean tools and how to lead by integrating guiding principles.After spending over a decade with the Shingo Institute he joined Munson Healthcare, northern Michigan'slargest healthcare system as their Chief Transformation Officer. At Munson Healthcare, Jacob spent sevenyears creating and deploying an organizational lean operating system and alignment framework anchored toguiding principles that are now integrated into nine hospitals and over 150 clinics. Currently Jacob supports the Shingo Institute as a Faculty Fellow by continuing his work in creating learning frameworks to help organizations effectively integrate the Shingo Model. He was recognized and awarded as alifetime member to the Shingo Academy in 2021 for his global contributions to operational excellence. Jacob continues to support various organizations through executive coaching and consulting. Current companies include: Amazon, General Motors, Android, UCLA Healthcare System, University of KansasHealthcare System and University of New Mexico Healthcare System Past organizations include: 3M, Raytheon Missile Systems, Boston Scientific, Boeing, Daimler, Intermountain Healthcare, Perrigo, Canadian Government-EDC, Switzerland Government-HealthcareLink to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Join host and Digital Education Chair Prashanthan Sanders, MBBS, PhD, FHRS, as he discusses this article from Nature with guests Anand N Ganesan, MBBS, PhD, and Tina Baykaner, MD, MPH. This trial was also presented as a late-breaking clinical trial at Heart Rhythm 2024.   https://www.hrsonline.org/education/TheLead https://www.nature.com/articles/s41591-025-03517-w   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): A. Ganesan: Honoraria/Speaking/Consulting: Biosense Webster, Inc. T. Baykaner: Honoraria/Speaking/Consulting: Medtronic, Pacemate, Volta Medical, iRhythm Technologies; Research: NIH   This episode is worth 0.25 ACE credits. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode99

This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for pulmonary vein isolation Conduction system pacing EHRA 2025 scientific highlights Host: Susanna Price Guests: Haran Burri, Isabel Deisenhofer, Helmut Puererfellner, Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1803   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week, we step In The Lobby with Brenda Becker, Senior Vice President of Global Government Affairs at Boston Scientific. With a career that spans state government, the private sector and the White House, Brenda brings a wealth of experience—and a heart rooted in Midwest values.In this conversation, Brenda reflects on the power of mentorship, something she's keenly known for across this town and the entire advocacy community. Whether it's guiding young professionals or offering seasoned advice to peers, her thoughtful, inclusive approach is a hallmark of her leadership.Brenda's story is a masterclass in public affairs—and in paying it forward. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit thefridayreporter.substack.com

Michael S. Lloyd, MD, FHRS, Emory University, is joined by Harish Doppalapudi, MD, FHRS, University of Alabama at Birmingham, to discuss this provocative article from late 2024 on Pulmonary Vein Isolation versus SHAM Intervention in Symptomatic Atrial Fibrillation. Special thanks to Prashant D. Bhave, MD, FHRS for his contributions to the discussion. https://www.hrsonline.org/education/TheLead https://jamanetwork.com/journals/jama/fullarticle/2823283#google_vignette Host Disclosure(s): M. Lloyd: Honoraria/Speaking/Consulting: Medtronic, Membership on Advisory Committees: Boston Scientific Contributor Disclosure(s): H. Doppalapudi: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Fellowship Support: Medtronic, Inc., Biosense Webster, Inc., Boston Scientific, Abbott Medical, Biotronik   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode97

Want to thrive in medical sales? In this episode, TJ, a regional business director specializing in cardiology, shares insider strategies for success—from fostering a growth mindset to mastering self-leadership. Learn how top performers refine their processes, understand their motivations, and leverage innovation to drive sales in coronary artery disease and structural heart technologies.   Discover why psychology beats tactical selling when building strong healthcare partnerships and how relationship-building is the key to long-term success. TJ also reveals how Boston Scientific onboards new reps to ensure they make an impact from day one, engaging effectively with hospital accounts.   Thinking about breaking into medical sales from a different industry? We explore how a restaurant server can successfully pivot into medical sales, the importance of demonstrating growth, and what hiring managers look for in standout candidates. Plus, get expert tips on acing interviews, crafting personalized follow-ups, and making authentic connections that lead to opportunities.   Whether you're a seasoned rep, an aspiring medical sales professional, or a leader looking to build a high-performing team, this episode is packed with real-world insights, career strategies, and actionable advice to help you succeed in the dynamic world of medical sales.   Meet the guest: TJ Jones is a Regional Sales Director for Boston Scientific, a global company that transforms lives through innovative medical solutions. He is passionate about positively impacting patient care and helping sales professionals reach new milestones professionally and personally. Connect with TJ: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!  

Alissa Coram and Justin Nielsen analyze Monday's market action and discuss key stocks to watch on Stock Market Today.

Do you ever wish you could be a fly on the wall at a tumor board meeting? In this episode of BackTable, we're excited to give you an insider's view of the real case discussions that take place during hepatocellular carcinoma (HCC) tumor boards. Host Dr. Zach Berman sits down with a multidisciplinary team, including Drs. Adam Burgoyne (medical oncologist), Heather Patton (hepatologist), Siddharth Padia (interventional radiologist), and Gabriel Schnickel (transplant and hepatobiliary surgeon). Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125743 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The team walks through a range of diverse HCC cases, reviewing patient histories, imaging, and treatment options. They cover eight cases in total, each featuring patients with varying treatment histories, comorbidities, liver function, and lesion characteristics. For the full educational experience, we recommend watching the video format on our YouTube channel. --- TIMESTAMPS 00:00 - Introduction 00:47 - Case 1: Small Lesion in a Young Patient 05:01 - Case 2: Moderate Sized Lesion in an Older Patient 11:10 - Case 3: Multifocal HCC with Dominant Lesion 21:09 - Case 4: Dominant Lesion with Portal Hypertension 32:08 - Case 5: Ruptured Solitary Lesion 34:34 - Case 6: Rupture with Multifocal Lesions 44:08 - Case 7: Portal Vein Invasion 52:12 - Case 8: Metastatic HCC After Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

William H. Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital, is joined by Arif Elvan, MD, PhD, Klinikum Braunschweig, and Usha B. Tedrow, MD, MS, FHRS, Brigham and Women's Hospital, to discuss if Voltage mapping could identify the conducting channels potentially responsible for ventricular tachycardia (VT). Standard thresholds (0.5–1.5 mV) were established using bipolar catheters. No thresholds have been analyzed with high-density mapping catheters. In addition, channels identified by cardiac magnetic resonance (CMR) have been proven to be related to VT. https://www.hrsonline.org/education/TheLead https://doi.org/10.1016/j.hrthm.2024.04.074 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): A. Elvan: Honoraria/Speaking/Consulting: Abbott Medical U. Tedrow: Honoraria/Speaking/Consulting/Teaching: Medtronic, Biosense Webster, Inc., St. Jude Medical, Thermedical, Boston Scientific, Baylis Medical Company   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode95

Are you seeking to build your reputation and patient base within interventional oncology? In this episode, host Dr. Zachary Berman interviews Dr. Siddarth Padia, Dr. Tyler Sandow, Dr. Kavi Krishnasamy, and Dr. Kevin Burns about their journeys into interventional oncology (IO) and their experiences providing care in different practice settings. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125742 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The doctors begin by discussing how they became interested in interventional oncology, with most of them recognizing opportunities to address unmet needs in the field. Each guest shares insights on the timelines and challenges involved in starting their IO practices, which vary significantly today. For instance, telehealth clinics are particularly viable in private practice IO, thanks to conferencing software and virtual translators. Hybrid care models, which combine in-person and remote consultations, can help overcome patient-level barriers such as time and transportation. The panel also emphasizes how increased clinic availability can significantly drive growth in procedural volume. Finally, they offer advice for starting an IO practice, including the importance of having clinic support staff, building strong relationships with referring physicians, and staying up to date with new technologies. --- TIMESTAMPS 00:00 - Introduction 05:38 - Balancing Career Interests and Expectations 07:10 - Building an Interventional Oncology Practice 13:42 - Gaining Trust from Referring Physicians 17:33 - Importance of Open Communication 19:19 - Comparing Clinic Settings 26:01 - Essential Components of a Clinic 33:28 - Narrowing Your Interventional Practice 40:09 - Introducing New Technology --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

Boston Scientific is looking at workforce planning in an entirely new way. We got the rare chance to hear all about it from Brenda Kowske, their Senior Director of Talent Analytics and Workforce Planning.With 50,000 employees worldwide and a rapidly growing footprint, they're navigating big challenges with fresh approaches.We talked with Brenda about how her team is breaking down traditional HR silos, integrating workforce planning into business decisions, and staying ahead of the curve with AI and skills-based planning.She's been in this space for over a decade and brings a sharp perspective on what works—and what doesn't.From creating global talent pods to using unexpected data like happiness indexes, Brenda walked us through how Boston Scientific is balancing data, technology, and strategy to make workforce planning a true competitive advantage.You will want to hear this episode if you are interested in...Intro [0:00]How AI is changing jobs, skills, and how teams are truly built [1:44]Using location and happiness data to make better workforce choices [2:29]The challenge of moving from job-based to skill-based planning [7:00]How to keep workforce data private while still using it smartly [21:00]Why Boston Scientific keeps workforce planning “always on” [24:30]How AI could make it easier to help employees grow their skills [33:20]Resources & People MentionedGDPR – General Data Protection Regulation OverviewCorporate Social Responsibility Directive (CSRD) – CSRD Information (European Commission)Anaplan – Anaplan Official WebsiteConnect with Brenda KowskeBrenda Kowske on LinkedInConnect With Red Thread ResearchWebsite: Red Thread ResearchOn LinkedInOn FacebookOn TwitterSubscribe to WORKPLACE STORIES

This week, join Isabel and Jade as they explore what's on the horizon for cardiac care, focusing on the revolutionary impact of remote monitoring with Angelo Auricchio, Chief Medical Officer, Rhythm Management, Boston Scientific.  He and Isabel discuss Angelo's recent career change into the industry, how technology could reform the UK's NHS, the role of remote monitoring in patient wellbeing and more.  A little more on EMJ GOLD's guest… Angelo Auricchio was appointed Chief Medical Officer, Rhythm Management, Boston Scientific in September 2024, where he works across the EMEA region. Prior to his time in industry, he gained a wealth of experience in academia and medicine, serving as Editor-in-Chief of the European Society of Cardiology's journal EP Europace and President of the European Heart Rhythm Association.    During his time in the medical field, he also served as Deputy Head of the Cardiology Department and Director of the Clinical Electrophysiology Unit at the Istituto Cardiocentro Ticino in Switzerland.   

En este episodio, desglosamos los eventos más relevantes que están impactando los mercados y la tecnología: Mercados atentos a aranceles y datos económicos: El $SPX, Nasdaq 100 y Dow operan estables mientras los inversionistas siguen la incertidumbre sobre los aranceles de Trump a México y Canadá. Además, analizamos el impacto de los próximos datos del PMI e ISM Manufacturing. Bitcoin se dispara por respaldo de Trump: $BTC-USD supera los $95K tras el anuncio de la Crypto Strategic Reserve y la primera Crypto Summit en la Casa Blanca. Evaluamos cómo esto afecta al mercado cripto y qué esperar en el sector. Boston Scientific adquiere SoniVie: $BSX pagará hasta $540M por una nueva terapia de hipertensión. Analizamos cómo esta compra refuerza su portafolio y qué impacto tendrá en su crecimiento. Honor apuesta por la IA: La compañía china invertirá más de $10B en IA en los próximos cinco años, presentando su estrategia en el MWC de Barcelona. Discutimos cómo esto posiciona a Honor en la competencia global de inteligencia artificial. AbbVie entra en el mercado de la obesidad: $ABBV firma un acuerdo con Gubra por hasta $2.2B para desarrollar un tratamiento experimental contra la obesidad. Evaluamos el impacto de esta inversión en el creciente sector farmacéutico. Acompáñanos para analizar cómo estos eventos están transformando los mercados financieros, la tecnología y la biotecnología. ¡Un episodio cargado de información clave!

Top Stories:1. Starbucks to lay off 1,100 corporate employeesSeattle Times article2. Seattle tech company adds to C-suitePSBJ article3. Sounders will give away tickets to first timersSeattle Times article or Sounders Press Release4. Pickleball chain coming to FremontSeattle Magazine article or PBSJ articleAbout guest co-hosts Lindsay Droz and Kristi Lord - Co-founders, L'AVANT:L'AVANT sells bougie, eco-friendly cleaning products with plant based ingredients like hand soap, dish soap, laundry detergent, multipurpose spray and more. Lindsay and Kristi started this company about 5 years ago. Lindsay has a sales and marketing background and worked in the medical device world, specifically for Boston Scientific for 15 years. Kristi worked in finance and investments and was the COO of an Asset Management company prior to L'AVANT.About host Rachel Horgan:Rachel is an independent event producer, emcee and entrepreneur. She worked for the Business Journal for 5 years as their Director of Events interviewing business leaders on stage before launching the weekly podcast. She earned her communication degree from the University of San Diego. Contact:Email: info@theweeklyseattle.comInstagram: @theweeklyseattleWebsite: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.theweeklyseattle.com⁠⁠

Is surgery truly the "cure" for hepatocellular carcinoma (HCC), and when is it a viable option? In this episode, Dr. Sabeen Dhand leads a roundtable discussion with interventional radiologist Dr. Siddharth Padia and transplant/hepatobiliary surgeons Dr. John Seal and Dr. Gabriel Schnickel, delving into the complexities of surgical treatments for HCC and the evolving landscape of liver resection and transplantation. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125741 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The doctors begin by discussing how they manage patient expectations regarding both palliative and curative treatments, highlighting the risk of recurrent HCC as a new lesion. They then outline key factors that influence their recommendations for liver transplant versus resection, such as the extent of underlying liver disease, the function of the future liver remnant, body habitus, overall health, and organ availability. The surgeons also review various surgical approaches to liver resection and recent advancements in liver transplantation, including living donor transplants and the ability to refer patients for downstaging procedures. Dr. Padia explains the original role of Y90 as a bridging treatment to downstage tumors and promote hypertrophy in the non-diseased liver segments, preparing the organ for surgical resection. However, Y90 treatment can also lead to the formation of adhesions, which may complicate future surgeries. Finally, the doctors discuss strategies to improve care coordination between community physicians and transplant centers to optimize patient outcomes. --- TIMESTAMPS 00:00 - Curative vs. Palliative Treatment 04:03 - Choosing Between Transplantation and Resection 05:47 - Liver Resection Types 07:27 - Bridging Role of Y90 12:14 - Evolving Landscape of Liver Transplantation 20:59 - Patient Counseling in Minimally Invasive Procedures 28:40 - Considerations for Surgery After Y90 33:32 - Coordination Between Specialists 40:08 - Immunotherapy as a Bridge to Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

In this episode of the DeviceTalks Weekly Podcast, it's a DeviceTalks Team Up. Editorial Director Tom Salemi and Managing Editor Kayleen Brown interview Doug Evans, CEO and President of Lungpacer Medical. Evans shares the tragic reason he vowed to start a company that would help wean patients off ventilators. We'll hear his success story in the podcast, but join us at DeviceTalks Boston to hear the story behind the AeroPace technologies as Evans will be joined by Lungpacer COO Viral Thakkar and Mike Longo, vice president of product development. Register to attend DeviceTalks Boston at Boston.DeviceTalks.com. If you missed our early bird rate use the code mentioned in the podcast on March 1 and 2. Before the DeepDive conversation, we'll have Mass Device Honcho Chris Newmarker's Newsmakers - Medtronic, Solventum, FDA layoffs, Boston Scientific, and Teleflex. Jim Hammerand, managing editor of Medical Design & Outsourcing, opens with an overview of the magazine's current Min-Vasive issue. You can find all the articles mentioned at medicaldesignandoutsourcing.com. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

William Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital is joined by Tobias Reichlin, MD, University Hospital Basel, Switzerland, and Nikolas Nozica, MD, Brigham and Women's Hospital, to discuss the Nature Medicine article Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. The following is a brief summary of the study covered in the article. Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study, we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF, and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis, or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profle by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.  https://www.hrsonline.org/education/TheLead https://doi.org/10.1038/s41591-024-03114-3 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): N. Nozica: Nothing to disclose. T. Reichlin: Nothing to disclose. This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode93

Maria Shepherd is the founder and CEO of Medi-Vantage, which helps companies develop disruptive medical devices and marketing strategies. Every strategy is designed to decrease risk, disrupt existing markets, and drive market share while improving patient outcomes. With clients from Japan, Australia, several EU countries, and the United States, Medi-Vantage has developed a comprehensive approach to global market entry, with services encompassing everything from developing engineering marketing specifications to conducting clinical due diligence for acquisitions.  As a guest on The Global Marketing Show, a Rapport International podcast, Maria shares her best advice from over 16 years of medical device strategy research, covering the commercialization continuum from marketing specifications through reimbursement, pricing strategy, and go-to-market planning. She also provides a roadmap for bringing medical devices to global markets: careful research and strategic pricing built upon a deep understanding of local healthcare systems.  The Complexities of Global Medical Device Pricing  Maria reports that thanks to increased transparency in the digital age, the days of setting different prices for different regions are essentially over. When a medical device is sold at a significantly lower cost in India, for instance, in the US, Germany, France, or Japan, economic buyers can easily access that information.  Transparency has forced companies to develop more sophisticated approaches to market entry in different regions. Some strategies include providing complementary capital equipment with the purchase of disposables or the implementation of subscription models. These approaches must be carefully considered, however, as some markets (like US hospitals) are known to resist certain pricing models. The key is finding a balance across different healthcare systems while maintaining profitability and market access.  Medi-Vantage develops budget impact models to help companies determine pricing and demonstrate value. Maria describes a recent project involving a device to help OB-GYNs make more informed decisions about C-sections. The model factored in:  Current C-section rates (36% in the US versus 24% globally)  Hospital costs associated with C-sections  Potential complications and ICU stays  Impact on mothers and babies  NICU costs  Associated litigation risks  Long-term implications like cerebral palsy  A comprehensive analysis quantifies immediate and long-term cost savings, making it easier for healthcare providers to justify the investment. Such models are particularly valuable when introducing disruptive technologies that require changes to established medical practices, Maria says, adding that:  We quantified all of those and put them into the budgetary impact model because, oftentimes, nobody really sees an alternative to C-section. They don't sit down and figure out, what if we didn't have to do this C-section? Then there are the costs to the mother, of complications, death, extreme impairment, or long hospitalization.  Clinical Due Diligence in Global M&A  Medi-Vantage also conducts clinical due diligence for medical technology companies considering acquisitions. Maria says it's not unusual for a surface-level appeal to fall short of reality, describing a rare instance in which she resisted an acquisition. A new technology promised to reduce a procedure requiring two in-hospital procedures to one hospital procedure plus one office visit, a clear win for efficiency and cost reduction.  During the due diligence process, however, the Medi-Vantage team uncovered significant resistance from both physicians and hospital administrators. The physicians were concerned about losing control of the second procedure to another specialist; hospital administrators worried about lost revenue. The feedback proved invaluable to their client's decision-making process, highlighting the importance of understanding local healthcare dynamics and stakeholder interests.  Advice for Global Market Entry  Medical device companies seeking global expansion face a complex web of challenges that extend far beyond basic market research. Standing out in a competitive market requires working with consultants who have deep expertise in specific medical specialties, she says, and a network of partners who understand both the clinical and business aspects of the device industry.  “It's important to seek out the people who can do the best for you, who understand the medical device specialty,” be it interventional cardiology or gastroenterology, regulatory requirements, translation, or another aspect. This targeted approach helps to prioritize the steps toward market acceptance based on unique workflows and decision-making processes.  The complexity extends beyond clinical knowledge. Market entry strategies must also account for local healthcare systems, reimbursement structures, and regulatory frameworks. “It's not easy,” Maria acknowledges. “You take into account what the reimbursement rates are, what types of insurance plans are available. There are many different factors, but what you want to be sure of is that you've got guardrails in place.”  Communication presents another critical challenge. Even with her own French language skills, Maria insists on working with specialized medical translators for international research. “I would never interview somebody in French and rely on my own French speaking skills,” she says. “I want to be sure that I get every single little nugget.” This attention to detail is particularly important in medical device marketing, where misunderstandings about product specifications or usage could have serious consequences.  While AI translation tools can be helpful for basic understanding, Maria stresses the importance of human expertise in medical translation, particularly for critical communications and research. High-quality translation from subject matter experts should be used for anything affecting revenue, liability, or the company's bottom line. For translation, interpreting, and research, for example, Maria looks for linguists who understand medical terminology in both source and target languages.  Maria's experience in North Africa crystallized for her the importance of understanding local market conditions. Learning the Arabic word “makesh” (meaning “there isn't any”) taught her that assumptions about product availability and market needs don't translate across borders. “In the United States, you can get almost anything, but that's not true in the rest of the world,” she observes. “Makesh is almost the standard.” This insight underscores why thorough market research conducted by experts who understand both the medical specialty and local healthcare environment is essential for successful global expansion.  For companies planning international expansion, Maria recommends a methodical approach:  Find consultants with relevant medical specialty expertise  Ensure all research and communication is handled by qualified professionals with appropriate language and clinical knowledge  Develop market entry strategies that account for local healthcare systems and cultural nuances  While COVID-19 accelerated many changes, Maria notes that these shifts were already underway. Industry leaders like Medtronic and Boston Scientific have evolved beyond traditional multinational models to become truly global organizations with unified branding, marketing, and communication strategies. The path forward is both challenging and clear, she says, adding that success will require moving beyond surface-level market research toward a deep and nuanced understanding of local healthcare dynamics, especially when “makesh is the standard.”  Links: Website: https://www.medi-vantage.com/  LinkedIn: https://www.linkedin.com/in/mariashepherd/ 

The process of liver transplantation involves many complexities, and each patient's path to transplant is unique. To offer insider perspectives on this process, Dr. Zachary Berman sits down with transplant and hepatobiliary surgeon Dr. John Seal, as well as transplant hepatologists Dr. Heather Patton and Dr. Steve Young. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125740 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The panel begins by discussing the multidisciplinary pre-transplant evaluation process, which assesses factors such as liver function, comorbidities, surgical risk, and the availability of psychosocial support. Once a patient is listed for transplant, they enter a system that prioritizes those with the highest Model for End-Stage Liver Disease (MELD) score. During the waiting period, several comorbidities should be carefully monitored. Dr. Seal explores the impact of portal vein hypertension and portal vein thrombosis, explaining how these conditions may necessitate intraoperative thrombectomy or bypass. Dr. Patton and Dr. Young focus on considerations for using anticoagulation in patients with a high baseline bleeding risk and selecting the appropriate anticoagulant for patients listed for transplant. For patients with hepatocellular carcinoma (HCC), eligibility for MELD exception points may depend on factors such as time spent on the waiting list, adherence to the Milan criteria, and the presence of extrahepatic complications of liver disease. The panel also discusses bridging therapies to transplant, including Y90 and TACE. In the peri-transplant phase, they highlight innovations such as living donor transplants, liver perfusion pumps, and the use of hepatitis C- and HIV-positive organs. Finally, the discussion turns to post-transplant considerations, including surgical complications, organ rejection, immunosuppression, predictors of HCC recurrence, and long-term surveillance. --- TIMESTAMPS 00:00 - Introduction 01:16 - Current Landscape of Liver Transplantation 03:22 - Transplant Evaluation Process 09:48 - Timeline from Listing to Transplantion 11:16 - Treating Portal Vein Thrombosis and Hypertension 18:44 - MELD Exception Points 22:05 - Bridging Therapies 25:34 - Peri-Transplant Considerations 30:53 - Post-Transplant Period 37:39 - Repeat Transplantation --- RESOURCES Model for end-stage liver disease (MELD) and allocation of donor livers (Wiesner et al, 2003): https://www.gastrojournal.org/article/S0016-5085%2803%2950022-1/fulltext Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis- Milan Criteria (Mazzaferro et al, 1996): https://pubmed.ncbi.nlm.nih.gov/8594428/ Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database (Mehta et al, 2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC6445634/ CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

William Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital is joined by Wendy Tzou, MD, FHRS, University of Colorado Anschutz Medical Campus, and Arif Elvan, MD, PhD, Klinikum Braunschweig, to discuss a partial delineation of targets for ablation of ventricular tachycardia (VT) during a stable rhythm is likely responsible for a suboptimal success rate. The abnormal low-voltage near-field functional components may be hidden within the high-amplitude far-field signal. https://www.hrsonline.org/education/TheLead https://doi.org/10.1016/j.jacep.2024.04.023 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): A.  Elvan: Honoraria/Speaking/Consulting: Abbott Medical  W. Tzou: Honoraria/Speaking/Consulting/Teaching: Medtronic, Biotronik, Mediasphere Medical, Biosense Webster, Inc., American Heart Association, Abbott, Boston Scientific, Membership on Advisory Committees: Medtronic, Inc., Biosense Webster, Inc., Kardium, BioTelemetry, Inc., Research: Abbott Medical This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode92

Ronald J. Bennett has an impressive track record of achievements, including serving as the Founding Dean and Professor Emeritus at the University of St. Thomas in St. Paul, Minnesota. He began his career in the industry, spending over 20 years in executive roles at BMC Industries, CPI (now Boston Scientific), Teltech, and several entrepreneurial organizations. Beyond his industry experience, Ron is also a dedicated educator and author, specializing in materials engineering, innovation, strategy, technology transfer, leadership, and engineering education.  Join the conversation as BJ and Ron dive into his inspiring story and remarkable career journey, what inspired his pursuit of an MBA, and what led to the founding of the School of Engineering at the University of St. Thomas. He unpacks his hope and inspiration for writing the book Leadership for Engineers: The Magic of Mindset (Basic Engineering Series and Tools), and shares his answers to our rapid-fire questions.  To hear more from Ron Bennett, be sure to tune in now! Key Points From This Episode:•   We are led through Ron Bennett's story: who he is, what he's done, and his career journey.•   Why he started the School of Engineering at the University of St. Thomas. •   His hope for Leadership for Engineers and the inspiration to take his curriculum and turn it into a book. •   What Ron is working on currently: The innovator's dilemma issue.  Quotes:“Part of this whole thing of leadership is use all the talent around you and recognize it [and] nurture it and help it grow.” — Ron Bennett  “You're going to be better at what you do if you're working on something that you're interested in.” — Ron Bennett  “Don't let the perfect be the enemy of the good.” — Ron Bennett  “The thing that I would most like is if someone talked about it that I inspired ordinary people to do extraordinary things for the common good, and for their own good for that matter.” — Ron Bennett  Links Mentioned in Today's Episode:Ron Bennett on LinkedInLeadership for Engineers: The Magic of Mindset (Basic Engineering Series and Tools)The Engineer's Guide to Authentic Leadership‘EMPOWERMENT: How to Overcome Limiting Beliefs'Leadership for EngineersBill George on LinkedInLet Your Life Speak: Listening for the Voice of VocationThe Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma'14 Grand Challenges for Engineers'The Obligation of the EngineerLeadership Blueprints PodcastMCFAMCFA CareersBJ Kraemer on LinkedIn

In this episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker sits down with Wayne Paterson, CEO of Anteris Technologies, a unique start-up that's approaching the complicated and competitive TAVR market. Chris Newsmaker and Host Tom Salemi also discuss this week's Newmarker's Newsmakers including Medtronic, Boston Scientific, Johnson & Johnson MedTech, NeuroPace and the FDA. This episode was sponsored by DeviceTalks Minnesota. Register to attend the June 11 event at Minnesota.DeviceTalks.com. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125739 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The discussion begins with an explanation of the Barcelona-Clinic Liver Cancer (BCLC) staging system. While this system takes into account helpful factors such as liver function, performance status, and tumor burden, it fails to fully capture the true heterogeneity of the HCC patient population. Additional considerations include tumor biology, response to previous treatments, and the location of metastases. The specialists then share their experiences in treating patients with comorbid gastrointestinal cancers and mixed tumors, discuss the benefits of an interventional oncology clinic setting, and highlight virtual opportunities for connecting with tumor boards. They also offer advice on patient education regarding treatment options. --- TIMESTAMPS 00:00 - Introduction to BCLC Staging 03:02 - Impact of Performance Status 06:29 - Predictors of Survival in HCC 09:51 - Palliative versus Curative Treatment Intent 13:55 - Comorbid and Mixed Gastrointestinal Cancers 16:51 - Adverse Effects of Treatment 20:37 - Interventional Oncology in the Clinic Setting 23:06 - Navigating Multiple Provider Viewpoints 28:01 - Complex Case Examples --- RESOURCES BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update (Reig et al, 2022): https://www.journal-of-hepatology.eu/article/S0168-8278(21)02223-6/fulltext CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf

In this episode of the DeviceTalks Weekly Podcast, Meghan Scanlon, SVP and president of urology at Boston Scientific, updates us on the integration of its powerhouse neurostim acquisition – Axonics. Scanlon also offers great insights on what makes the urology business such a powerful specialty for physicians and medical device executives. Go here to listen to Scanlon's first visit with DeviceTalks Weekly. https://www.devicetalks.com/boston-scientific-and-zenflow-are-bringing-critical-new-tools-to-help-urologists-treat-patients/ DeviceTalks Managing Editor Kayleen Brown sits down with Kevin Dempsey, senior director of business development at Tecan, about the opportunities in neuromodulation. Tecan is the sponsor of this episode. To learn more about Tecan visit, https://partnering.tecan.com/ MassDevice Editor Chris Newmarker brings a basket of Newmarker's Newsmakers including Inspire Medical, Kestra Medical, MGB Layoffs, Medtronic and Johnson & Johnson. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss an episode.

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi talks with Dr. Maria Artunduaga, the founder and CEO of Samay, a startup that's using acoustic energy to get a clearer picture of the lung's performance. Family tragedy and professional frustration set Dr. Artunduaga on a course that won MedTech Innovator's Grand Prize. She has the giant check to prove it. This episode was sponsored by DeviceTalks Boston. You can register at Boston.DeviceTalks.com. Rachel Robinson, COO of MassMEDIC, joins us on the Newmarker's Newsmakers. Before we hit the news of the week, Robinson gave a preview of the upcoming MassMEDIC's Symposium & Gala on March 6. Go to MassMEDIC.com for more information. MassDevice Executive Editor Chris Newmaker then delivers news on - Boston Scientific, ResMed, Globus Medical, BD and Baxter. Hilarity ensues. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.